Prometheus Biosciences, Inc. (RXDX)
| Market Cap | 1.01B |
| Revenue (ttm) | 1.91M |
| Net Income (ttm) | n/a |
| Shares Out | 38.81M |
| EPS (ttm) | -3.84 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 208,468 |
| Open | 25.01 |
| Previous Close | 24.96 |
| Day's Range | 24.87 - 26.38 |
| 52-Week Range | 16.11 - 30.64 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings Date | Nov 10, 2021 |
About RXDX
Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of precision therapeutics and companion diagnostics products for the treatment and diagnosis of inflammatory bowel diseases (IBD). Its products include PRA023, a Phase I clinical trial IgG1 humanized monoclonal antibody (mAb); PR600, an anti- tumor necrosis factor mAb for IBD; PR300, a G-protein coupled receptor modulator small molecule for IBD; PR1800, anti-chemokine mAb for IBD; and PR2100, an anti-inflammatory cytokine mAb ...
Financial Performance
In 2020, RXDX's revenue was $1.23 million, an increase of 9.93% compared to the previous year's $1.12 million. Losses were -$37.14 million, 24.9% more than in 2019.
Financial StatementsNews
Prometheus Biosciences to Present at Jefferies Virtual Next Generation IBD Therapeutics Summit
SAN DIEGO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), today announced that Mark McKenna, Chairman and Chief Executive Officer and Allison Luo, M.D., Chief Medical Off...
Prometheus Biosciences Reports Second Quarter 2021 Financial Results and Highlights Recent Corporate Progress
- Initiated Phase 2 study of PRA023 and its companion diagnostic in Ulcerative Colitis (UC) and Phase 2a study of PRA023 and its companion diagnostic in Crohn's disease (CD) -
In Memoriam – Friend, Scientific Innovator, Advisor and Board Chair Dr. Tadataka Yamada Has Passed Away
SAN DIEGO, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), with great sorrow announced today that its Chairman of the Board, Tadataka (Tachi) Yamada, M.D., KBE, passed awa...
Prometheus Biosciences Announces Initiation of APOLLO-CD Phase 2a Clinical Trial of PRA023 in Moderate-to-Severe Croh...
- First Anti-TL1A trial in Crohn's Disease -
Prometheus Biosciences Achieves Milestone Payment from Dr. Falk Pharma GmbH Further Validating the Prometheus360™ Pla...
-Prometheus receives $10 million payment triggered by selection of clinical candidate for PR600-
Prometheus Biosciences to Present at 2021 Jefferies Virtual Healthcare Conference
SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, a...
3 Small Cap Stocks That Are Short Squeeze Candidates
Low float stocks can be some of the most volatile stocks in the market. If you mix in a short squeeze, the potential short-term gains in a low float stock can be extreme.
Prometheus Biosciences to Present at 2021 RBC Capital Markets Global Healthcare Conference
SAN DIEGO, May 14, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, a...
3 Short Squeeze Candidates In The Health Care Sector
Low float stocks can be some of the most volatile stocks in the market. If you mix in a short squeeze, the potential short-term gains in a low float stock can be extreme.
Why Auris Medical, CytoDyn and Prometheus Shares Are Moving Today
Auris Medical Holding Ltd. (NASDAQ: EARS), CytoDyn Inc. (OTC: CYDY) and Prometheus Biosciences, Inc. (NASDAQ: RXDX) are among the biggest movers in the biopharma space Thursday.
Steven Cohen Dives Deeper Into Health Care
Steven Cohen ( Trades , Portfolio ) has revealed a new buy into Prometheus Biosciences Inc. (NASDAQ:RXDX) alongside an addition to his position in Curis Inc. (NASDAQ:CRIS) according to GuruFocus Real-Ti...
The Past Week's Notable Insider Buys Include Coupang, Keurig Dr Pepper, IPOs And More
Insider buying can be an encouraging signal for potential investors, especially when markets are near all-time highs. Some insiders took advantage of initial public offerings in the past week.
Prometheus Biosciences Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purc...
SAN DIEGO, March 16, 2021 /PRNewswire/ -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a biotechnology company pioneering a precision medicine approach for the discovery, development, and commercializat...
Prometheus Biosciences Announces Upsized Pricing of Initial Public Offering
Prometheus Biosciences, Inc. (Nasdaq: RXDX), a biotechnology company pioneering a precision medicine approach for the discovery, development,...
Phase 1 biotech Prometheus Biosciences files for a $125 million IPO
Prometheus Biosciences, a Phase 1 biotech developing precision antibody therapies for IBD and related diseases, filed on Friday with the SEC to raise up to $125 million in an initial public offering.
Prometheus Biosciences IPO Registration Document (S-1)
Prometheus Biosciences, Inc. has filed to go public with an IPO on the NASDAQ.